August 18, 2017 1:09 PM ET


Company Overview of Polaris Pharmaceuticals, Inc.

Company Overview

Polaris Pharmaceuticals, Inc. engages in research and development of protein drugs to treat cancer. The company was founded in 2006 and is based in San Diego, California.

9373 Towne Centre Drive

Suite 150

San Diego, CA 92121

United States

Founded in 2006





Key Executives for Polaris Pharmaceuticals, Inc.

Chief Executive Officer and President
Co-Founder and Vice President of Medical Affairs
Executive Vice-President of Regulatory Affairs
Executive Director
Compensation as of Fiscal Year 2017.

Polaris Pharmaceuticals, Inc. Key Developments

Polaris Group Reports Phase III Study Results of ADI-PEG 20 plus Best Supportive Care in Advanced Hepatocellular Carcinoma

Polaris Group announced that the phase III study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma (HCC) did not meet its primary endpoint of demonstrating overall survival (OS) benefits. Median OS was 7.8 months for ADI-PEG 20 vs. 7.4 months for placebo (p = 0.884, HR=1.022 [95% CI: 0.847, 1.233]). However, analysis of study data revealed that patients with arginine depletion for 7 weeks or longer had a median OS of 12.5 months, compared to 6.3 months (P < 0.0001) for patients with arginine depletion lasting less than 7 weeks. It is believed that treating patients with ADI-PEG 20 depletes circulating arginine, thus starving cancer cells of arginine, which is an essential amino acid for these cancers. These results in the starved cancer cells being unable to survive and grow while leaving the body's normal cells unharmed. The statistically significant findings from the analysis of the study data appear to support this hypothesis. Additionally, sorafenib naïve patients appear to have benefited more than those who failed prior sorafenib treatment, suggesting that ADI-PEG 20 may be more efficacious in the first-line setting. The study also showed ADI-PEG 20 was well tolerated, with the most common side effects being fatigue and decrease of appetite. The full study results were presented at a plenary session by the lead investigator, Dr. Ghassan K. Abou-Alfa from the Memorial Sloan Kettering Cancer Center, at the American Society of Clinical Oncology's 2016 annual meeting in Chicago. ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers carrying a major metabolic defect that renders them unable to internally synthesize arginine. Because arginine is essential for protein synthesis and survival of cells, these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to deplete the external supply of arginine, causing arginine-dependent cancer cells to die while leaving the patient's normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency and can potentially be treated with ADI-PEG 20.

Polaris Pharmaceuticals, Inc. Presents at ChinaBio Leadership Retreat 2015, Oct-22-2015

Polaris Pharmaceuticals, Inc. Presents at ChinaBio Leadership Retreat 2015, Oct-22-2015 . Venue: Changshu, China.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Polaris Pharmaceuticals, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at